Literature DB >> 1525624

Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis.

K Forslind1, K Eberhardt, A Jonsson, T Saxne.   

Abstract

Two cartilage specific macromolecules, cartilage oligomeric matrix protein (COMP) and proteoglycan, were quantified by immunoassay in sera of two groups of patients with rheumatoid arthritis (RA) of recent onset to evaluate the prognostic value of such measurements. Patients with rapidly progressive joint destruction had increased COMP concentrations initially, which subsequently decreased. A group with more benign disease, and less extensive joint damage, had normal COMP levels throughout the study period. Serum concentrations of proteoglycan were normal in both groups. Thus measurement of COMP in serum early in the course of RA holds promise as a prognostic marker for development of joint destruction in this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525624     DOI: 10.1093/rheumatology/31.9.593

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  20 in total

1.  Enhanced COMP catabolism detected in serum of patients with arthritis and animal disease models through a novel capture ELISA.

Authors:  Y Lai; X-P Yu; Y Zhang; Q Tian; H Song; M T Mucignat; R Perris; J Samuels; S Krasnokutsky; M Attur; J D Greenberg; S B Abramson; P E Di Cesare; C J Liu
Journal:  Osteoarthritis Cartilage       Date:  2012-05-14       Impact factor: 6.576

2.  Cartilage oligomeric matrix protein/thrombospondin-5 (COMP/TSP-5) levels do not correlate to functional class in patients with rheumatoid arthritis.

Authors:  Fernanda Duarte Andrade; Ana Lígia Bender; Inês Guimarães da Silveira; Helga Stein; Carlos Alberto von Mühlen; Henrique Luiz Staub
Journal:  Clin Rheumatol       Date:  2009-08-30       Impact factor: 2.980

3.  Different mechanical loading protocols influence serum cartilage oligomeric matrix protein levels in young healthy humans.

Authors:  A Niehoff; U G Kersting; S Helling; J Dargel; J Maurer; M Thevis; G-P Brüggemann
Journal:  Eur J Appl Physiol       Date:  2010-06-11       Impact factor: 3.078

4.  Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now?

Authors:  A R Poole
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

5.  Cartilage oligomeric matrix protein in serum in systemic lupus erythematosus and knee osteoarthritis. Preliminary communication.

Authors:  M Wisłowska; B Jabłońska
Journal:  Rheumatol Int       Date:  2005-03-01       Impact factor: 2.631

6.  Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study.

Authors:  T Conrozier; T Saxne; C S Fan; P Mathieu; A M Tron; D Heinegård; E Vignon
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

7.  Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.

Authors:  M Skoumal; G Haberhauer; J Feyertag; E M Kittl; K Bauer; A Dunky
Journal:  Rheumatol Int       Date:  2006-02-17       Impact factor: 2.631

8.  Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis.

Authors:  L S Lohmander; T Saxne; D K Heinegård
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

9.  Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis.

Authors:  H Forsblad D'Elia; A Larsen; E Waltbrand; G Kvist; D Mellström; T Saxne; C Ohlsson; E Nordborg; H Carlsten
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

10.  Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis.

Authors:  Susan Tseng; A Hari Reddi; Paul E Di Cesare
Journal:  Biomark Insights       Date:  2009-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.